Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials

Executive Summary

Progression-free survival is an appropriate primary endpoint to support the approval of metastatic melanoma therapies, FDA's Oncologic Drugs Advisory Committee agreed

You may also be interested in...



Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal

Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense

Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal

Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense

Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS043989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel